Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126983&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 02/04/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 02/04/2025
|
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126951&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 02/03/2025
|
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126839&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RVNC
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126703&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 02/03/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC
- NEW YORK , Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 02/03/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RVNC
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126534&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
RVNC STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 02/02/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126489&wire=1 or contact Joseph E. Levi, Esq.
- 02/01/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 02/01/2025
|
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RVNC
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126430&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
- 01/31/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/31/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126375&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- LOS ANGELES , Jan. 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) have opportunity to lead the securities fraud class action lawsuit.
- 01/31/2025
|
Shareholders That Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Pending Class Action - RVNC
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126246&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
- SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 01/31/2025
|
Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline
- Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 JOHNSON CITY, Tenn.
- 01/31/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126229&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/31/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
- NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/31/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/30/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join – Contact Levi & Korsinsky
- NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/30/2025
|
Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126110&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/30/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit - RVNC
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126077&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125998&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/30/2025
|
The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK , Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/30/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125934&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/29/2025
|
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
- NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).
- 01/29/2025
|
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125844&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- BENSALEM, Pa. , Jan. 29, 2025 /PRNewswire/ -- The Law Offices of Howard G.
- 01/29/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125707&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/29/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125569&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/28/2025
|
Revance Therapeutics, Inc. Securities Fraud Lawsuit Pending
- WASHINGTON, DC / ACCESS Newswire / January 28, 2025 / Cohen Milstein alerts investors that a complaint was filed on January 3, 2025 in the U.S. District Court for the Middle District of Tennessee against Revance Therapeutics, Inc. ("Revance" or the "Company") (Nasdaq:RVNC), a biotechnology company that develops and commercializes neuromodulators. The complaint alleges that Revance, Mark.
- 01/28/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125548&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/28/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/28/2025
|
Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/28/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125429&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125405&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
- NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/27/2025
|
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
- NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/27/2025
|
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125261&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/27/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
- NEW YORK , Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/27/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125213&wire=1 or contact Joseph E. Levi, Esq.
- 01/26/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
- 01/26/2025
|
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125192&wire=1 or contact Joseph E. Levi, Esq.
- 01/26/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/26/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125150&wire=1 or contact Joseph E. Levi, Esq.
- 01/26/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Revance Therapeutics, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/26/2025
|
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=125002&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/24/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124974&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/24/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124929&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Revance Therapeutics, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/24/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/24/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/23/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124690&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- LOS ANGELES , Jan. 23, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). IF YOU SUFFERED A LOSS ON YOUR REVANCE INVESTMENTS, CLICK HERE BEFORE MARCH 4, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
- 01/23/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124649&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit - RVNC
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124633&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/23/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Revance Therapeutics, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/23/2025
|
Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/23/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RVNC
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124515&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge and Revance and Encourages Investors to Contact the Firm
- NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQ: BIOA) and Revance Therapeutics, Inc. (NASDAQ:RVNC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
- 01/22/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124507&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
Shareholder Rights Law Firm Robbins LLP Reminds RVNC Shareholders with Large Losses to Seek Counsel for the Revance Therapeutics, Inc. Class Action
- SAN DIEGO , Jan. 22, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
- 01/22/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESSWIRE / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/22/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC
- NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/22/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124425&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/22/2025
|
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124401&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/22/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124367&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
RVNC Stockholders Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/22/2025
|
Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Pending Class Action - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124167&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/21/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124132&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/21/2025
|
The Gross Law Firm Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RVNC
- NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).
- 01/21/2025
|
Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/21/2025
|
Investors Who Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Pending Class Action - RVNC
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=124096&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
RVNC Shareholders Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/21/2025
|
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
- JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer.
- 01/21/2025
|
Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/21/2025
|
Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123965&wire=1 or contact Joseph E. Levi, Esq.
- 01/20/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
- 01/20/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/20/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
- NEW YORK, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123904&wire=1 or contact Joseph E. Levi, Esq.
- 01/20/2025
|
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Jan. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/20/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/20/2025
|
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/20/2025
|
Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/20/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK--(BUSINESS WIRE)---- $RVNC #RVNC--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rev.
- 01/19/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 19, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123702&wire=1 or contact Joseph E. Levi, Esq.
- 01/19/2025
|
Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/19/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 19, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123672&wire=1 or contact Joseph E. Levi, Esq.
- 01/19/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/19/2025
|
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc.(RVNC)
- NEW YORK, NY / ACCESSWIRE / January 18, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123596&wire=1 or contact Joseph E. Levi, Esq.
- 01/18/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/18/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/18/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit - RVNC
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123539&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/17/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/17/2025
|
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123474&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- LOS ANGELES , Jan. 17, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) have opportunity to lead the securities fraud class action lawsuit.
- 01/17/2025
|
Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/17/2025
|
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
- NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123432&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/17/2025
|
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
- NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/17/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
- NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/16/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
- NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/16/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/16/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/16/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/16/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/16/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123246&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
RVNC Shareholders with Large Losses are Encouraged to Seek Counsel to Lead the Revance Therapeutics, Inc. Class Action - Contact Robbins LLP Today
- SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ:RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
- 01/15/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123210&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/15/2025
|
Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).
- 01/15/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123156&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- BENSALEM, Pa. , Jan. 15, 2025 /PRNewswire/ -- The Law Offices of Howard G.
- 01/15/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RVNC
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123139&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/15/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit - RVNC
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=123104&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/15/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122951&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/14/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122886&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
- 01/14/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/14/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122849&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/14/2025
|
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122807&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/14/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/13/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122588&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/13/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122569&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
Revance Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/13/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122544&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/13/2025
|
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
- JOHNSON CITY, Tenn. , Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax withholding.
- 01/13/2025
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
- NEW YORK , Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/13/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122332&wire=1 or contact Joseph E. Levi, Esq.
- 01/12/2025
|
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122310&wire=1 or contact Joseph E. Levi, Esq.
- 01/12/2025
|
RVNC STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/12/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESSWIRE / January 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/12/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 11, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122245&wire=1 or contact Joseph E. Levi, Esq.
- 01/11/2025
|
Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/11/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK--(BUSINESS WIRE)---- $RVNC #RVNC--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rev.
- 01/10/2025
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Revance Therapeutics Inc.
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
- 01/10/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122126&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122059&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/10/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=122044&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/10/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121956&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
Kirby McInerney LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Class Action Filing and Encourages Investors to Contact the Firm
- NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company.
- 01/10/2025
|
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
- 01/10/2025
|
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RVNC
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121911&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/10/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121815&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , Jan. 9, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/09/2025
|
Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121781&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
Revance Therapeutics, Inc. Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Against RVNC
- SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ:RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
- 01/09/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Dedlinea
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121756&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/09/2025
|
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121744&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/09/2025
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
- NEW YORK , Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/09/2025
|
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121590&wire=1 or contact Joseph E. Levi, Esq.
- 01/08/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join – Contact Levi & Korsinsky
- NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
- 01/08/2025
|
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121516&wire=1 or contact Joseph E. Levi, Esq.
- 01/08/2025
|
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
- LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
- 01/08/2025
|
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121504&wire=1 or contact Joseph E. Levi, Esq.
- 01/08/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/08/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121379&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”). Investors have until March 4, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 01/07/2025
|
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 01/07/2025
|
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121328&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit
- SAN DIEGO , Jan. 7, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
- 01/07/2025
|
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121301&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
- 01/07/2025
|
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action.
- 01/07/2025
|
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - RVNC
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121231&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. (RVNC)
- NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee on behalf of all persons or entities who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance Therapeutics” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”).
- 01/07/2025
|
Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121228&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/07/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121105&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). Revance investors have until March 4, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOS.
- 01/06/2025
|
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). Revance investors have until March 4, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REVANCE THERAPEUTICS, INC. (RVNC), CONTACT THE LAW OFFICES OF.
- 01/06/2025
|
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121017&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/06/2025
|
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=121003&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
- ATLANTA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Revance's business, operations, and prospects, including allegations that: (i) Revance was in material breach of its distribution agreement with Teoxane SA; (ii) the foregoing subjected Revance to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that Crown Laboratories, Inc.'s tender offer to acquire all outstanding shares of the Company's common stock would be delayed and/or amended.
- 01/06/2025
|
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
- 01/06/2025
|
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
- Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA , Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (Nasdaq: RVNC) to acquire Revance for $3.60 per share in cash. Teoxane beneficially owns 6.2% of the outstanding shares of common stock of Revance.
- 01/06/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Revance Therapeutics, Inc. and Certain Officers -RVNC
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 01/03/2025
|
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $3.10 in cash for each share of Revance that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
- 12/17/2024
|
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the revised transaction, Revance stockholders will receive only $3.10 per share in cash, less than one-half of the August 2024 purc.
- 12/12/2024
|
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share
- Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in cash.
- 12/12/2024
|
Revance agrees to lower-priced buyout offer by Crown Laboratories
- Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said on Monday.
- 12/09/2024
|
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
- JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement.
- 12/09/2024
|
Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029
- The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies. The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies.
- 11/29/2024
|
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
- NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/08/2024
|
Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC
- PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).
- 11/08/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/08/2024
|
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.
- 11/07/2024
|
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Revance Therapeutics, Inc. (RVNC)
- NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/06/2024
|
Revance Therapeutics, Inc. (RVNC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
- NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/06/2024
|
Revance Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Revance Therapeutics, Inc. (RVNC)
- NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/04/2024
|
Revance Therapeutics, Inc. Being Investigated on Behalf of Revance Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.
- NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/02/2024
|
Revance Therapeutics, Inc. (RVNC) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
- NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 11/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/31/2024
|
Lost Money on Revance Therapeutics, Inc. (RVNC)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 10/30/2024
|
Revance Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Revance Therapeutics, Inc. (RVNC)
- NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 10/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/29/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Revance Therapeutics, Inc. (RVNC) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 10/29/2024
|
Shareholders That Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Securities Fraud Investigation - RVNC
- NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 10/28/2024
|
Revance Therapeutics, Inc. Being Investigated on Behalf of Revance Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
- NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
- 10/28/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/17/2024
|
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a notice to remedy alleged material breach.
- 10/17/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required ef.
- 10/15/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Revance investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.
- 10/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/09/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/03/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 09/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 09/27/2024
|
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for Revance Therapeutics (RVNC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 09/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).
- 09/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
- NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 09/24/2024
|
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
- The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 08/29/2024
|
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $6.66 in cash for each share of Revance that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
- 08/15/2024
|
Shareholder Alert: Ademi LLP investigates whether Revance Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
- MILWAUKEE , Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation https://www.ademilaw.com/case/revance-therapeutics-inc-0 or call Guri Ademi toll-free at 866-264-3995.
- 08/15/2024
|
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNC
- NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Revance Therapeutics , Inc. ( Nasdaq : RVNC ) , relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.
- 08/13/2024
|
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/13/2024
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.
- NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Revance Therapeutics, Inc. (NASDAQ: RVNC) and its board of directors concerning the proposed acquisition of the company by Crown Laboratories, Inc. Stockholders will receive $6.66 for each share of Revance Therapeutics stock that they hold. The transaction is valued at approximately $924 million and is expected to close by the end of 2024.
- 08/12/2024
|
Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
- Revance Therapeutics (NASDAQ: RVNC ) stock is on the rise Monday after the biotechnology company announced a merger agreement with private skincare company Crown Laboratories. This agreement has Crown Laboratories agreeing to acquire Revance Therapeutics for $924 million.
- 08/12/2024
|
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
- Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. RVNC.
- 08/12/2024
|
RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories
- MONSEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance”) to Crown Laboratories, Inc. (“Crown”) for $6.66 per share in cash in a tender offer.
- 08/12/2024
|
Anti-wrinkle injection maker Revance to go private in $924 million deal
- Anti-wrinkle injection maker Revance Therapeutics will be acquired by private skincare company Crown Laboratories in a take-private deal worth $924 million, including debt, the two companies said on Monday.
- 08/12/2024
|
Crown Laboratories and Revance Announce Entry Into Merger Agreement
- Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the strength of both organizations JOHNSON CITY, Tenn. and NASHVILLE, Tenn.
- 08/12/2024
|
Revance Therapeutics, Inc. (RVNC) Q2 2024 Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations Mark Foley - Chief Executive Officer & President Tobin Schilke - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Chris Shibutani - Goldman Sachs Stacy Ku - TD Cowen David Amsellem - Piper Sandler Annabel Samimy - Stifel Lachlan Hanbury - William Blair Uy Ear - Mizuho Serge Belanger - Needham & Company Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Second Quarter 2024 Financial Results And Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 08/09/2024
|
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.80 per share a year ago.
- 08/08/2024
|
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024.
- 08/01/2024
|
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
- Just like in the sport of baseball, it's generally better to put one foot in front of the other: get on base and move the guy on first to second and so on until you score a run. However, if you're the San Diego Padres and you find yourself behind by 10 runs (usually to a terrible team), it's time to swing for the fences.
- 07/11/2024
|
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
- 06/14/2024
|
Revance to Participate in Upcoming Investor Conferences
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Investor Conferences.
- 05/28/2024
|
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Revance Therapeutics (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 05/24/2024
|
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains
- Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.
- 05/22/2024
|
3 Underappreciated Stocks That Could 10x in 10 Years
- Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.
- 05/12/2024
|
Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript
- Revance Therapeutics Inc. (NASDAQ:RVNC ) Q1 2024 Results Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations, New Street IR Mark Foley - Chief Executive Officer Tobin Schilke - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Partners Stacy Ku - TD Cowen Annabel Samimy - Stifel Financial Chris Shibutani - Goldman Sachs David Amsellem - Piper Sandler Daniel Ziment - Morgan Stanley Serge Belanger - Needham & Co. Lachlan Hanbury-Brown - William Blair Navann Ty - Exane BNP Paribas Operator Welcome to the Revance Therapeutics First Quarter2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 05/09/2024
|
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.74 per share a year ago.
- 05/09/2024
|
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update.
- 05/09/2024
|
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia.
- 05/09/2024
|
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024.
- 05/02/2024
|
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.
- 04/12/2024
|
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
- 03/27/2024
|
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $100 Million Public Offering of Common Stock.
- 03/04/2024
|
Revance Announces Proposed Public Offering of Common Stock
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Proposed Public Offering of Common Stock.
- 03/04/2024
|
Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript
- Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript
- 02/29/2024
|
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update.
- 02/28/2024
|
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.
- 02/21/2024
|
Revance to Participate in Upcoming Investor Conferences
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Investor Conferences.
- 02/21/2024
|
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®.
- 02/02/2024
|
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference.
- 02/01/2024
|
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook.
- 01/08/2024
|
Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Seamus Fernandez - Guggenheim Partners Mikaela Franceschina - Barclays David Amsellem - Piper Sandler Stacy KU - TD Cowen Annabel Samimy - Stifel Uy Ear - Mizuho Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Terence Flynn - Morgan Stanley Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.
- 11/08/2023
|
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/08/2023
|
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
- NASHVILLE--(BUSINESS WIRE)--Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update.
- 11/08/2023
|
Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
- Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.
- 09/15/2023
|
3 Healthcare Stocks to Sell in September Before They Crash & Burn
- The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.
- 09/06/2023
|
3 Very Oversold Biotech Stocks to Buy Right Now
- After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.
- 08/29/2023
|
Revance shares gain 8% after FDA approval of cervical dystonia treatment
- Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.
- 08/14/2023
|
Revance's Botox rival gets FDA approval for painful neck muscle condition
- The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.
- 08/14/2023
|
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.
- 08/08/2023
|
After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)
- Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 07/13/2023
|
7 Healthcare Stocks to Make You the Millionaire Next Door
- Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.
- 06/21/2023
|
This Botox Rival Has Investors Smiling With A 100% Gain This Year. The Stock Broke Out Today.
- Revance Therapeutics, a biotech stock, is at a 52-week high and reports earnings Tuesday. Their frown line treatment lasts longer than Botox.
- 05/09/2023
|
Top 4 Stocks Set to Beat on Earnings Today After Market Closes
- We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.
- 05/09/2023
|
7 Stocks to Buy for the Massive Rally Ahead
- Well-known investment advisor Ed Yardeni believes that U.S. stocks are poised to rally this year. Speaking to CNBC last week, Yardeni said that the banking mini-crisis will be “very well-contained” by the Federal Reserve and Federal Deposit Insurance Corporation (FDIC).
- 04/04/2023
|
Revance Therapeutics: Rally Seems Due For A Pause
- Today, we take a deeper look at Revance Therapeutics, Inc., a developer of aesthetic products that is seeing rapid revenue growth. The company has potential catalysts on the horizon but is bumping up against analyst price targets and has a high cash burn rate.
- 04/03/2023
|
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
- Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.
- 03/02/2023
|
Revance Therapeutics, Inc. (RVNC) Q4 2022 Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Company Participants Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Annabel Samimy – Stifel Seamus Fernandez – Guggenheim Securities Stacy Ku – Cowen Balaji Prasad – Barclays Lachlan Hanbury-Brown – William Blair Terence Flynn – Morgan Stanley Douglas Tsao – H.C. Wainwright Serge Belanger – Needham & Company Operator Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call.
- 02/28/2023
|
Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
What Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now?
- Does Revance Therapeutics, Inc. (RVNC) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 02/02/2023
|
JPMorgan Chase Cuts Stake in Revance Therapeutics
- Fintel reports that Jpmorgan Chase & Co has filed a 13G/A form with the SEC disclosing ownership of 4.98MM shares of Revance Therapeutics Inc (RVNC).
- 01/30/2023
|
3 Pharma Stocks That Will Mint Millionaires
- In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year.
- 01/30/2023
|
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
- Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
- 01/27/2023
|
Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?
- Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 01/23/2023
|
Carpe Diem, Daxxify: Revance Therapeutic Preps For An Exciting Year
- The global Botulinum Toxin market should reach $9.09 billion by 2029. Technically, Revance Therapeutics, Inc.'s DAXXIFY is the first time in over 30 years that a truly innovative neurotoxin has been brought to the aesthetics market.
- 01/19/2023
|
Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey
- FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc. A competing drug by the name of BOTOX was estimated to have generated more than $14.6 billion in sales in 2021.
- 11/14/2022
|
Revance Therapeutics, Inc. (RVNC) Q3 2022 Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 11/08/2022
|
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
- Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.
- 10/17/2022
|
Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up
- FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.
- 09/09/2022
|
Revance Shares Jump 17% After FDA Approves Botox Rival
- Revance Therapeutics says its new treatment, Daxxify, diminishes facial wrinkles for up to six months.
- 09/08/2022
|
Why Is Revance Therapeutics (RVNC) Stock Soaring Today?
- Revance Therapeutics (NASDAQ: RVNC ) stock is jumping 12% and trending on social media today. The company announced this morning that the Food and Drug Administration (FDA) had approved its alternative to Botox.
- 09/08/2022
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2022 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jessica Serra - Head-Investor Relations and ESG Mark Foley - Chief Executive Officer Toby Schilke - Chief Financial Officer Conference Call Participants Operator Welcome to the Revance Therapeutics Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 08/09/2022
|
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
- 08/02/2022
|
Revance: Potential Comeback On FDA Resubmission For DAXI
- Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027.
- 07/14/2022
|
Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin – Needham Operator Welcome to the Revance Therapeutics' First Quarter 2022 Financial Results and Corporate Update Conference Call.
- 05/10/2022
|
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
3 Top Biotech Stocks To Watch This Week
- Should you be paying attention to these biotech stocks right now?
- 03/22/2022
|
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?
- Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 03/22/2022
|
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/21/2022
|
Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
- NASHVILLE--(BUSINESS WIRE)--Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at 2021 ASDS Annual Meeting
- 11/19/2021
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 4.35% and -1.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings?
- Revance Therapeutics (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/08/2021
|
Revance Therapeutics: Repricing Shares After A CRL
- I've been very bullish on Revance Therapeutics' novel long acting neuromodulator since December 2019.
- 10/29/2021
|
Lost Money in Revance Therapeutics, Inc.?
- OAKLAND, Calif.--(BUSINESS WIRE)---- $RVNC--Gibbs Law Group is investigating potential claims on behalf of Revance investors.
- 10/18/2021
|
RVNC EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC
- NEW YORK, Oct. 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) resulting from allegations that Revance may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Revance securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 10/18/2021
|
Revance Therapeutics Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 18, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Revance Therapeutics, Inc. ("Revance Therapeutics" or the "Company") (NASDAQ: RVNC).If you suffered losses exceeding $50,000 investing in Revance Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for...
- 10/18/2021
|
Ademi LLP Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.
- MILWAUKEE, Oct. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Revance (NASDAQ: RVNC). The investigation results from inaccurate statements Revance may have made regarding its business operations and prospects.
- 10/18/2021
|
Revance Therapeutics Stock Nosedives on FDA News
- Revance Therapeutics Inc (NASDAQ:RVNC) is plummeting today, last seen down 41.9% to trade at $13.21.
- 10/18/2021
|
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES , Oct. 18, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/18/2021
|
REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
- Boston, Massachusetts--(Newsfile Corp. - October 18, 2021) - Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations. Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/rvnc.What is this all about?On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance...
- 10/18/2021
|
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
- The Nasdaq looks poised to open slightly lower after a strong week.
- 10/18/2021
|
Revance Therapeutics plummets after FDA said it can't approve BLA of treatment for frown lines
- Shares of Revance Therapeutics Inc. RVNC, +0.66% plummeted 34.7% toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a Complete Response Letter (CRL) regarding the biotechnology company's treatment of glabellar, or frown, lines. The company said late Friday that FDA determined it could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility.
- 10/18/2021
|
Why Revance Therapeutics Stock Is Getting Crushed Today
- A surprise rejection is weighing on the biopharma's shares today.
- 10/18/2021
|
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Revance--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of Revance stockholders. Our investigation concerns whether Revance has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 12, 2021, the U.S. Food and Drug Administration (
- 10/15/2021
|
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
- 10/15/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $RVNC #RVNC--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc.
- 10/14/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- SAN FRANCISCO, Oct. 14, 2021 /PRNewswire/ -- Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/RVNC Contact An Attorney Now: RVNC@hbsslaw.com 844-916-0895 Revance Therapeutics, Inc. (RVNC) Investigation: Revance Therapeutics plans to compete in the Botulinum toxin market dominated by Allegan's BOTOX.
- 10/14/2021
|
RVNC Stock: Why It Substantially Increased Today
- The stock price of Revance Therapeutics Inc (NASDAQ: RVNC) increased by over 12% today. This is why it happened.
- 10/13/2021
|
Why Revance Therapeutics Stock Is Bolting Higher Today
- Management's response to a publicly disclosed regulatory form has investors doing a U-turn.
- 10/13/2021
|
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
- 10/12/2021
|
REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
- Boston, Massachusetts--(Newsfile Corp. - October 12, 2021) - Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations. Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/rvnc.What is this all about?On October 12, 2021, the U.S. Food and Drug Administration (FDA) posted Form 483 to its website citing issues...
- 10/12/2021
|
Revance Therapeutics: Frowning At The FDA
- Despite the recent selloff, shares of Revance Therapeutics are up 65% since I gave a very bullish recommendation 2 years ago. In that time, we have have seen an equity raise, acquisition of sales rights for RHA fillers from Teoxane, a convertible note offering and of course the COVID-19 pandemic.
- 08/15/2021
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2021 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
- Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 6.14% and 12.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2021 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Recap: Revance Therapeutics Q1 Earnings
- Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the past year to ($1.08), which beat the estimate of ($1.09).
- 05/10/2021
|
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
- NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
- 04/06/2021
|
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
- Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 03/22/2021
|
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
- Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness about appearance along with the increasing pool of geriatric population is the primary driver that is estimated to catapult the facial injectable market to new heights during the forecast period. Moreover, the increasing shift towards minimally invasive procedures and continuous developers in glacial rejuvenation is expected to further augment the growth for the same market. Additionally, the rising awareness regarding the accessibility of various products and procedures, which has stemmed due to the increasing number of players entering the facial injectables space across the globe is forecasted to further add to the surge that the market is expected to witness. Besides, the importance of skincare has gained quite a momentum as exemplified by the fact that 71,800 jobs in 2018 were held by skincare specialists, 47% of which were employed by personal care services in the United States. Additionally, the projected employment in 2028 is estimated at 79,600 [Source: U.S. Bureau of Labor Statistics]. Further, individualistic value-driven rational has superseded the generic mob mentality of the yesteryears which incentivizes today's consumers to look for products that more oriented to themselves. Further, this interest has also fueled investments in various research studies like that of DREAM (Dysport Real-world Evaluation and Measured satisfaction study) carried out by Galderma after which in May 2020, it announced 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients believed the result of the treatment looked natural. Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. In the same year, HUONS announced that the Korean Ministry of Food and Drug Safety has given it the approval to conduct phase 2 clinical trials for Liztox, its independently developed botulinum toxin (BTX) product that has launched in June 2019, for treating square jaws. Moreover, form the perspective of increasing market reach, in 2020 Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering innovations in neuromodulators for aesthetic and therapeutic indications, announced the signing of a U.S. distribution agreement with TEOXANE SA. Under this agreement, Revance is the exclusive commercialization partner of the Swiss company's modern and innovative Resilient Hyaluronic Acid (RHA) technology. TEOXANE's RHA line of fillers include U.S. Food and Drug Administration (FDA)-approved RHA 2, RHA 3, and RHA 4 products, which include lidocaine. The RHA line was designed using a patented crosslinking method that preserves the hyaluronic acid network for correction of moderate-to-severe dynamic facial wrinkles and folds optimizing strength, stretch, and tissue integration. It provides physicians with a broad range of uniquely designed gels for individualized treatment in the face. Further due to the upward trend there has been a new development in the aesthetics armlet particularly that pertaining to the facial Injectable market. For instance, in 2020, despite the COVID 19, Galderma announced that "Restylane Kysse" - it's lip filler lip augmentation product, received FDA. Again, Revance Therapeutics, Inc recently announced that the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI), which is its next generation neuro modular product aimed at treating moderate to severe glabellar (frown) lines, has been accepted for review by the U.S. Food and Drug Administration (FDA). In 2019 The HydraFacialT Company announced that it has entered into a partnership with Advanced Dermatology and Cosmetic Surgery, the largest dermatology practice in the United States. Furthermore, Allergan plc (NYSE: AGN) announced that it received U.S. Food and Drug Administration (FDA) approval for the use of Juvederm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDET cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21 years. In 2018, Restylane Lyft with Lidocaine, by Q-Med AB was approved by FDA for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds, subcutaneous to subperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21. Thus, from the aforesaid, it is evident that the facial injectable market is expected to witness a significant rise during the forecast period, nevertheless, certain adverse effects Viz. allergic reactions, nausea, skin rash, as well as neck and back pain, are expected to deter the growth. Further regularity issues pertaining to botulinum toxin type A, is also expected to pose a hindrance to market growth during the forthcoming years. Key Topics Covered: 1. Introduction 1.1. Market Definition1.2. Market Segmentation 2. Research Methodology 2.1. Research Data2.2. Assumptions 3. Executive Summary 3.1. Research Highlights 4. Market Dynamics 4.1. Market Drivers4.2. Market Restraints4.3. Porters Five Forces Analysis4.3.1. Bargaining Power of Suppliers4.3.2. Bargaining Power of Buyers4.3.3. The threat of New Entrants4.3.4. Threat of Substitutes4.3.5. Competitive Rivalry in the Industry4.4. Industry Value Chain Analysis 5. Facial Injectable Market Analysis, By Type 5.1. Introduction5.2. Botulinum Toxin5.3. Collagen5.4. Hyaluronic Acid5.5. Particle & Polymer Fillers (PPF)5.5.1. Calcium Hydroxyapatite5.5.2. Poly-l-Lactic Acid5.5.3. Polymethylmethacrylate 6. Facial Injectable Market Analysis, By Generation 6.1. Introduction6.2. Gen X6.3. Boomer6.4. Millennials 7. Facial Injectable Market Analysis, By End-User 7.1. Introduction7.2. Dermatology & Beauty Clinics7.3. Hospitals7.4. Research Institutes 8. Facial Injectable Market Analysis, by Geography 8.1. Introduction8.2. North America8.2.1. North America Facial Injectable Market Analysis, By Product Type8.2.2. North America Facial Injectable Market Analysis, By Generation8.2.3. North America Facial Injectable Market Analysis, By End-Users8.2.4. By Country8.2.4.1. USA8.2.4.2. Canada8.2.4.3. Mexico8.3. South America8.3.1. South America Facial Injectable Market Analysis, By Product Type8.3.2. South America Facial Injectable Market Analysis, By Generation8.3.3. South America Facial Injectable Market Analysis, By End-Users 8.3.4. By Country8.3.4.1. Brazil8.3.4.2. Argentina8.3.4.3. Others8.4. Europe8.4.1. Europe Facial Injectable Market Analysis, By Product Type8.4.2. Europe Facial Injectable Market Analysis, By Generation8.4.3. Europe Facial Injectable Market Analysis, By End-Users8.4.4. By Country8.4.4.1. Germany8.4.4.2. France8.4.4.3. United Kingdom8.4.4.4. Italy8.4.4.5 Others8.5. The Middle East and Africa8.5.1. Middle East and Africa Facial Injectable Market Analysis, By Product Type8.5.2. Middle East and Africa Facial Injectable Market Analysis, By Generation8.5.3. Middle East and Africa Facial Injectable Market Analysis, By End-Users8.5.4. By Country8.5.4.1. Israel8.5.4.2. Saudi Arabia8.5.4.3. Others8.6. Asia Pacific8.6.1. Asia Pacific Facial Injectable Market Analysis, By Product Type8.6.2. Asia Pacific Facial Injectable Market Analysis, By Generation8.6.3. Asia Pacific Facial Injectable Market Analysis, By End-Users8.6.4. By Country8.6.4.1. China8.6.4.2. Japan8.6.4.3. South Korea8.6.4.4. India8.6.4.5. Others 9. Competitive Environment and Analysis 9.1. Major Players and Strategy Analysis9.2. Emerging Players and Market Lucrativeness9.3. Mergers, Acquisitions, Agreements, and Collaborations9.4. Vendor Competitiveness Matrix 10. Company Profiles 10.1. Allergan (AbbVie Inc)10.2. Bausch Health Companies Inc.10.3. Bloomage Biotechnology Corporation Limited10.4. Galderma 10.5. Johnson Medical Aesthetics, LLC10.6. Merz Pharma10.7. Prollenium Medical Technologies10.8. Sanofi 10.9. Sinclair Pharma10.10. Suneva Medical For more information about this report visit https://www.researchandmarkets.com/r/4fn9up
- 02/24/2021
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript
- 02/22/2021
|
Recap: Revance Therapeutics Q4 Earnings
- Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24), which were in line with the estimate of ($1.24).
- 02/22/2021
|
Revance Therapeutics's Earnings Outlook
- On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.
- 02/19/2021
|
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
- Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
- 11/27/2020
|
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
- Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Recap: Revance Therapeutics Q3 Earnings
- Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.34), which missed the estimate of ($1.03).
- 11/09/2020
|
